The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two decades. Historically, therapeutic strategies primarily focused on ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Joel Schectman is a national security reporter for The Wall Street Journal in Washington. He focuses on espionage, covert action and digital surveillance. Joel returned to the Journal after more ...

Inflammatory bowel disease is a chronic condition of unknown origin characterized by severe inflammation and mucosal destruction in the intestine. There are two main forms: Crohn s disease, which ...